The Bioverge Podcast: Bridging the Translational Science Divide

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

continue reading >

The Bioverge Podcast: Investing in the Bio-Based Future

Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

continue reading >

The Bioverge Podcast: From Bugs to Drugs

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

continue reading >

The Bioverge Podcast: A Wall Street Veteran Discusses Where Biotech Has Been and What's Ahead

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

continue reading >

The Bioverge Podcast: Accelerating Timelines and The Bioverge Podcast: Improving Outcomes with a Predictive Precision Medicine Platform

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

continue reading >

The Bioverge Podcast: Changing Drug Discovery with Transomics

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

continue reading >

The Bioverge Podcast: Engineering Intelligence into Cell and Gene Therapies

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

continue reading >

The Bioverge Podcast: Addressing the Challenges of Chronic Liver Disease

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

continue reading >

The Bioverge Podcast: Curing Blindness with Cell Therapy

On this episode, Arnaud Lacoste, Chief Scientific Officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

continue reading >

Volumetric to be acquired by 3D Systems ($DDD) in a deal worth up to $400M

Congratulations to the Volumetric team on their acquisition by 3D Systems!

continue reading >
Media

The Bioverge Podcast: Bridging the Translational Science Divide

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

Continue Reading >
Media

The Bioverge Podcast: Investing in the Bio-Based Future

Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

Continue Reading >
Media

The Bioverge Podcast: From Bugs to Drugs

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

Continue Reading >
Media

The Bioverge Podcast: A Wall Street Veteran Discusses Where Biotech Has Been and What's Ahead

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

Continue Reading >
Media

The Bioverge Podcast: Accelerating Timelines and The Bioverge Podcast: Improving Outcomes with a Predictive Precision Medicine Platform

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

Continue Reading >
Media

The Bioverge Podcast: Changing Drug Discovery with Transomics

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

Continue Reading >
Media

The Bioverge Podcast: Engineering Intelligence into Cell and Gene Therapies

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

Continue Reading >
Media

The Bioverge Podcast: Addressing the Challenges of Chronic Liver Disease

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

Continue Reading >
Media

The Bioverge Podcast: Curing Blindness with Cell Therapy

On this episode, Arnaud Lacoste, Chief Scientific Officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

Continue Reading >
Health + Tech, Investing, Startups

Volumetric to be acquired by 3D Systems ($DDD) in a deal worth up to $400M

Congratulations to the Volumetric team on their acquisition by 3D Systems!

Continue Reading >
Next